Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: The possibility of repeat infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises questions regarding quality and longevity of the virus-induced immune response.
METHODS: The antibody course and memory B-cell (MBC) response against SARS-CoV-2 proteins, influenza virus nucleoprotein (NP), and tetanus toxin were examined in adults with mild to moderate SARS-CoV-2 infection in the first year after infection.
RESULTS: The concentration of SARS-CoV-2 receptor binding domain (RBD)-specific antibodies was low compared with the concentration of influenza virus NP-specific antibodies. The SARS-CoV-2 RBD antibody half-life increased from 95 days in the first 6 months to 781 days after 9-12 months. The SARS-CoV-2 NP antibody half-life increased from 88 to 248 days. Two thirds of the subjects had SARS-CoV-2-specific MBC responses 12 months after infection. The SARS-CoV-2 antibody levels correlated with the MBC frequency at 12 months.
CONCLUSIONS: The low concentration of SARS-CoV-2 spike protein antibodies indicates that re-exposure to the virus or vaccination are required to use the B-cell immunity to full capacity. The existence of a robust SARS-CoV-2 MBC response at 12 months in most subjects and the substantially increasing antibody half-life provide evidence that the immune response is developing into long-term immunity. The early antibody reaction and the ensuing MBC response are interdependent.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:226 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 226(2022), 4 vom: 04. Sept., Seite 664-672 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kannenberg, Judith [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 25.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiac034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336385331 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336385331 | ||
| 003 | DE-627 | ||
| 005 | 20231225232026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiac034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336385331 | ||
| 035 | |a (NLM)35104869 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kannenberg, Judith |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 25.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The possibility of repeat infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises questions regarding quality and longevity of the virus-induced immune response | ||
| 520 | |a METHODS: The antibody course and memory B-cell (MBC) response against SARS-CoV-2 proteins, influenza virus nucleoprotein (NP), and tetanus toxin were examined in adults with mild to moderate SARS-CoV-2 infection in the first year after infection | ||
| 520 | |a RESULTS: The concentration of SARS-CoV-2 receptor binding domain (RBD)-specific antibodies was low compared with the concentration of influenza virus NP-specific antibodies. The SARS-CoV-2 RBD antibody half-life increased from 95 days in the first 6 months to 781 days after 9-12 months. The SARS-CoV-2 NP antibody half-life increased from 88 to 248 days. Two thirds of the subjects had SARS-CoV-2-specific MBC responses 12 months after infection. The SARS-CoV-2 antibody levels correlated with the MBC frequency at 12 months | ||
| 520 | |a CONCLUSIONS: The low concentration of SARS-CoV-2 spike protein antibodies indicates that re-exposure to the virus or vaccination are required to use the B-cell immunity to full capacity. The existence of a robust SARS-CoV-2 MBC response at 12 months in most subjects and the substantially increasing antibody half-life provide evidence that the immune response is developing into long-term immunity. The early antibody reaction and the ensuing MBC response are interdependent | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody course | |
| 650 | 4 | |a antibody half-life | |
| 650 | 4 | |a memory B-cells | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Trawinski, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Henschler, Reinhard |e verfasserin |4 aut | |
| 700 | 1 | |a Buhmann, Raymund |e verfasserin |4 aut | |
| 700 | 1 | |a Hönemann, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Jassoy, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 226(2022), 4 vom: 04. Sept., Seite 664-672 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:226 |g year:2022 |g number:4 |g day:04 |g month:09 |g pages:664-672 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiac034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 226 |j 2022 |e 4 |b 04 |c 09 |h 664-672 | ||